Arrowhead appoints Hongbo Lu to board; expands to 8 members

ARROWHEAD PHARMACEUTICALS, INC.

Hongbo Lu, Ph.D., appointed as independent director effective April 1, 2024, increasing board from 7 to 8.
Lu brings over 20 years of healthcare investment experience, including Managing Partner at Vivo Capital and LAV.
She receives standard non-employee director compensation plus sign-on RSU grant valued at $761,666 vesting over three years.
No family relationships or material interests with Arrowhead directors or officers disclosed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hongbo Lu

Director

ARWR · ARROWHEAD PHARMACEUTICALS, INC.

Effective: 2024-04-01
Filed: February 22, 2024, 6:59 PM ET

On February 21, 2024, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) announced that it would increase the size of the Company's board of directors ("Board") from seven to eight members and appoint Hongbo Lu, Ph.D., as an independent director of the Company, effective April 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hongbo Lu was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

On February 21, 2024, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) announced that it would increase the size of the Company's board of directors ("Board") from seven to eight members and appoint Hongbo Lu, Ph.D., as an independent director of the Company, effective April 1, 2024.

View on SEC.gov

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-24-005998

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.